| SCT200 / Sinocelltech |
NCT03405272: Safety and Efficacy of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Wild-type RAS and BRAF mCRC |
|
|
| Unknown status | 2 | 110 | RoW | Recombinant Anti-EGFR Monoclonal Antibody（SCT200） | Sinocelltech Ltd., Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Metastatic Colorectal Cancer | 12/18 | 12/19 | | |
NCT03692689: Safety and Efficacy of SCT200 in Patients With Relapsed or Metastatic Triple Receptor Negative Breast Cancer |
|
|
| Unknown status | 2 | 30 | RoW | SCT200 | Sinocelltech Ltd. | Triple Negative Breast Neoplasms | 09/19 | 12/19 | | |
NCT03744208: SCT200 Injection in Patients With Head and Neck Squamous Cell Carcinoma |
|
|
| Unknown status | 2 | 30 | NA | Anti-EGFR monoclonal antibody, SCT200 | Shi Yuankai | Head and Neck Squamous Cell Carcinoma | 12/19 | 05/20 | | |
NCT03713372: Safety and Efficacy of SCT200 in Head and Neck Squamous Cell Carcinoma |
|
|
| Unknown status | 2 | 40 | RoW | Anti-EGFR monoclonal antibody, SCT200 | Sinocelltech Ltd., Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Head and Neck Cancer | 02/20 | 05/20 | | |
NCT03874741: SCT200 Plus Platinum-based Chemotherapy in Head and Neck Squamous Cell Carcinoma |
|
|
| Unknown status | 2 | 25 | RoW | SCT200, Anti-EGFR monoclonal antibody | Sinocelltech Ltd. | Head and Neck Squamous Cell Carcinoma | 06/20 | 07/21 | | |
| Unknown status | 1/2 | 50 | RoW | recombinant anti-EGFR monoclonal antibody, SCT200 | Sinocelltech Ltd., Tianjin Medical University Cancer Institute and Hospital | Esophageal Squamous Cell Carcinoma | 11/19 | 05/20 | | |
